Who is sponsoring NCT03492515?

NCT03492515 is sponsored by Shandong University.

What drugs are being tested in NCT03492515?

Interventions in NCT03492515: recombinant human thrombopoietin, Platelet Concentrate.

What condition does NCT03492515 study?

NCT03492515 studies Immune Thrombocytopenia.

Is NCT03492515 still recruiting?

NCT03492515 is currently status unknown. Last updated 10 April 2018.

Last reviewed 2018-04-10 · How we verify

NCT03492515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia

Status unknown Phase 3 Last updated 10 April 2018

What this trial tests

Phase 3 trial testing recombinant human thrombopoietin in Immune Thrombocytopenia in 90 participants. Status unknown.

Timeline

1 May 2018

Primary endpoint
1 May 2020

1 May 2022

Quick facts

Lead sponsor	Shandong University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 May 2018
Primary completion	1 May 2020
Estimated completion	1 May 2022
Sites	1 location across China

Drugs / interventions tested

recombinant human thrombopoietin — full drug profile →
Platelet Concentrate — full drug profile →

Conditions studied

Immune Thrombocytopenia — all drugs for Immune Thrombocytopenia →

Sponsor

Shandong University

Who can join

Adults 18 to 50, female only, with Immune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to observe the clinical efficacy and adverse reactions of rhTPO in the treatment of pregnancy-induced thrombocytopenia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

[How I treat primary immune thrombocytopenia in pregnancy].
Wang L, Hou M. · · 2019 · PMID 32023725 · DOI 10.3760/cma.j.issn.0253-2727.2019.12.001

Verify or expand the search:

Other trials of recombinant human thrombopoietin

Trials testing the same drug.

NCT03673215 — The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment · EARLY_PHASE1 · unknown

Other recruiting trials for Immune Thrombocytopenia

Currently open trials in the same condition.

NCT07104565 — Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Diso · Phase 2 · recruiting
NCT07007962 — Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed · Phase 3 · recruiting
NCT07216079 — Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan · Phase 3 · active not recruiting
NCT06776510 — A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia · Phase 1, PHASE2 · recruiting
NCT06715215 — Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia · NA · recruiting

Other Shandong University trials

Trials by the same sponsor.

NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03492515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong University
Last refreshed: 10 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03492515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing